Fig. 7
From: Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
PBMC-mediated cytotoxicity against nucleolin-positive MDA-MB-231 cells in vitro. Tumor cells and PBMCs were cocultured and treated with PBS, free PD-1 aptamer, free AS1411 aptamer, or BiApt in the medium. After 72 h, unattached PBMCs were washed off, and tumor cells were evaluated for viability with standard MTS assay (n = 7, mean + SEM). Star indicates statistically significant differences (p < 0.05)